3265. Misbranding of Triple Sulfonamides tablets, Dexedrine Sulfate tablets,
diethylstilbestrol tablets, and pentobarbital sodium capsules.   U. S. v.
K Carl E. Neels.    Plea of guilty.    Fine, $1,100.    (F. D. Q. No. 29435,
SamRle Nos. 60867-K, 60868-K, 60938-K, 60939-K, 6Q954-K, 6Q955-K,
. : 6Q974^K.)  .;
INFORMATION FILED':   July 25; 1950, Eastern District of Missouri, against Carl
B. Neels, a pbarniacist for Neels Dirugs, St. Iiouis, Mo.
INTERSTATE SHIPMENT : From the States of Ohio, Pennsylvania,' Indiana, and
New York, into the State of Missouri, of quantities of Triple Sulfonamides
tablets, Dexedrine Sulfate tablets, diethylstilbestrol tablets, and pentobarbital
sodium capsules.
ALLEGED VIOLATION : On or about August 4, 20, 22, fcnd 25, 1949, while the drugs
were being held for sale after shipment in interstate commerce, the defendant
caused various quantities of such drugs to be repacked' and sold without a
prescription, which acts resulted in the repackaged drugs being misbranded.
NATURE OF CHARGE: Misbranding, Section 502 (b) (i), the repackaged drugs,
with the exception of the diethylstilbestrol tablets failed to bear labels con-
taining the name and place of business of the manufacturer, packer, or dis-
tributor; and, Section 502 (b) (2), all of the repackaged drugs failed to bear
labels containing an accurate statement of the quantity of the contents.
Further mishranding Section 502 (d), the pentobarbital sodium capsules
contained a chemical derivative of barbituric acid, which derivative has been
found to be, and by regulations designated as, habit forming; and the label of
the repackaged pentobarbital sodium capsules failed to bear the name and
quantity of such derivative and in juxtaposition therewith the statement
"Warning-May be habit forming."
Further misbranding, Section 502 (e) (2), the Triple Sulfonamides tablets
were fabricated from two or more ingredients, and when repackaged, their
label failed to bear the common or usual name of each active ingredient; and,
Section 502 (f) (1), the labeling of all of the repackaged drugs failed to
bear adequate directions for use.
Further misbranding, Section 502 (f) (2), the labeling of the repackaged
Triple Sulfonamides tablets and diethylstilbestrol tablets bore no warnings
against use in those pathological conditions where their use may be dangerous
to health, and against unsafe dosage and methods and duration of admin-
istration.
DISPOSITION : August 18, 1950. A plea of guilty having been entered, the court
imposed a fine of $1,100.